{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:11:55Z","timestamp":1761894715163},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.beha.2007.09.007","type":"journal-article","created":{"date-parts":[[2008,4,17]],"date-time":"2008-04-17T16:33:54Z","timestamp":1208450034000},"page":"783-795","source":"Crossref","is-referenced-by-count":9,"title":["Is there still a role for allogeneic stem-cell transplantation in multiple myeloma?"],"prefix":"10.1016","volume":"20","author":[{"given":"William I.","family":"Bensinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2007.09.007_bib1","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/ncponc0174","article-title":"Drug insight: thalidomide as a treatment for multiple myeloma","volume":"2","author":"Kumar","year":"2005","journal-title":"Nature Clinical Practice Oncology"},{"key":"10.1016\/j.beha.2007.09.007_bib2","series-title":"Hematology 2002: American Society of Hematology Education Program Book","first-page":"214","article-title":"Multiple myeloma","author":"Anderson","year":"2002"},{"key":"10.1016\/j.beha.2007.09.007_bib3","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: Proof of principle","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.09.007_bib4","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0140-6736(96)90871-5","article-title":"Graft-versus-myeloma effect in two cases","volume":"347","author":"Verdonck","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2007.09.007_bib5","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0140-6736(05)64525-4","article-title":"Graft-versus-myeloma effect","volume":"348","author":"Aschan","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2007.09.007_bib6","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.bmt.1703253","article-title":"Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect","volume":"28","author":"Le Blanc","year":"2001","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.beha.2007.09.007_bib7","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/sj.bmt.1701980","article-title":"Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation","volume":"24","author":"Libura","year":"1999","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.beha.2007.09.007_bib8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/sj.leu.2400546","article-title":"Adoptive immunotherapy for relapsed multiple myeloma after allogeniec bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect","volume":"11","author":"Bertz","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.09.007_bib9","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bmt.1702685","article-title":"Donor leukocyte infusions for multiple myeloma","volume":"26","author":"Salama","year":"2000","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.beha.2007.09.007_bib10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2007.09.007_bib11","unstructured":"Alyea E, Ritz J., Induction of graft-versus-myeloma by donor lymphocyte infusions following allogeneic bone marrow transplant. In Anderson KC (ed) VI International Workshop on Multiple Myeloma 1997."},{"key":"10.1016\/j.beha.2007.09.007_bib12","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/sj.bmt.1701459","article-title":"Graft-versus-myeloma","volume":"22","author":"Mehta","year":"1998","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.beha.2007.09.007_bib13","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.bbmt.2004.06.002","article-title":"Relapse to prior autograft and chronic graft-vs-host disease are the strongest prognostic factors for outcome of melphalan\/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma","volume":"10","author":"Kroger","year":"2004","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"Part 1","key":"10.1016\/j.beha.2007.09.007_bib14","first-page":"635a","article-title":"Allografts after reduced intensity conditioning can induce long-term remission in patients with chemosensitive relapsed multiple myeloma (MM)","volume":"100","author":"Einsele","year":"2002","journal-title":"Blood"},{"issue":"supplement 1","key":"10.1016\/j.beha.2007.09.007_bib15","first-page":"669a","article-title":"Response to donor lymphocyte infusions (DLI) of patients with CML in relapse after allografting: a long-term follow-up study using RT-PCR","volume":"94","author":"Cwynarski","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.09.007_bib16","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood.V96.8.2712","article-title":"Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"96","author":"Dazzi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.09.007_bib17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/10428199809068567","article-title":"Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation","volume":"29","author":"Helg","year":"1998","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.beha.2007.09.007_bib18","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0041-1345(98)01603-0","article-title":"Mixed hematopoietic chimerism after hematopoietic stem cell allografts","volume":"31","author":"Storb","year":"1999","journal-title":"Transplantation Proceedings"},{"key":"10.1016\/j.beha.2007.09.007_bib19","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects","volume":"97","author":"McSweeney","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.09.007_bib20","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","article-title":"Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma","volume":"102","author":"Maloney","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.09.007_bib21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0301-472X(02)01010-X","article-title":"Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning","volume":"31","author":"Lee","year":"2003","journal-title":"Experimental Hematology"},{"issue":"Part 1","key":"10.1016\/j.beha.2007.09.007_bib22","first-page":"859a","article-title":"Non-myeloablative allogeneic transplantation as part of salvage therapy for relapse of multiple myeloma after autologous transplantation","volume":"100","author":"Hoepfner","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.09.007_bib23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.bmt.1703652","article-title":"Fludarabine\/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma","volume":"30","author":"Giralt","year":"2002","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.beha.2007.09.007_bib24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1046\/j.1365-2141.2003.04299.x","article-title":"Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning","volume":"121","author":"Einsele","year":"2003","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.09.007_bib25","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/cncr.21700","article-title":"Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma","volume":"106","author":"Qazilbash","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2007.09.007_bib26","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/ajh.20641","article-title":"Prolonged overall survival with second on-demand autologous transplant in multiple myeloma","volume":"81","author":"Elice","year":"2006","journal-title":"American Journal of Hematology"},{"key":"10.1016\/j.beha.2007.09.007_bib27","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2002-01-0131","article-title":"Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma","volume":"100","author":"Kroger","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.09.007_bib28","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1182\/blood-2002-04-1150","article-title":"Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality","volume":"100","author":"Kroger","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.09.007_bib29","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.leukres.2005.01.017","article-title":"Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation","volume":"29","author":"Galimberti","year":"2005","journal-title":"Leukemia Research"},{"key":"10.1016\/j.beha.2007.09.007_bib30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/bbmt.2003.50009","article-title":"Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity","volume":"9","author":"Peggs","year":"2003","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1016\/j.beha.2007.09.007_bib31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.bmt.1704531","article-title":"Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation","volume":"34","author":"Mohty","year":"2004","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.beha.2007.09.007_bib32","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2004-06-2387","article-title":"Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT","volume":"105","author":"Crawley","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.09.007_bib33","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1182\/blood-2006-07-036848","article-title":"Reduced intensity conditioning for myeloma: lower non-relapse mortality but higher relapse rates compared to myeloablative conditioning","volume":"109","author":"Crawley","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.09.007_bib34","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.09.007_bib35","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood-2003-12-4435","article-title":"Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation","volume":"103","author":"Kroger","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.09.007_bib36","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A comparison of allografting with autografting for newly-diagnosed myeloma","volume":"356","author":"Bruno","year":"2007","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2007.09.007_bib37","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2007.09.007_bib38","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/sj.bmt.1701362","article-title":"Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma","volume":"22","author":"Majolino","year":"1998","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.beha.2007.09.007_bib39","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1182\/blood-2002-10-3250","article-title":"166HO-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: Results of two phase 1\/2 trials","volume":"102","author":"Giralt","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.09.007_bib40","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/sj.leu.2403575","article-title":"A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma","volume":"19","author":"Dispenzieri","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.09.007_bib41","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.leu.2403698","article-title":"Outcome of myeloablative allogeneic stem cell transplantation in multiple myeloma with a 153Sm-EDTMP-based preparative regimen","volume":"19","author":"Kennedy","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2007.09.007_bib42","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJM200101183440303","article-title":"Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers","volume":"344","author":"Bensinger","year":"2001","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2007.09.007_bib43","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/00006231-200211000-00010","article-title":"153Sm EDTMP for bone marrow ablation prior to stem cell transplantation for haematological malignancies","volume":"23","author":"Macfarlane","year":"2002","journal-title":"Nuclear Medicine Communications"},{"issue":"Part 1","key":"10.1016\/j.beha.2007.09.007_bib44","first-page":"179a","volume":"100","author":"Giralt","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.09.007_bib45","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2002-02-0527","article-title":"Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome","volume":"100","author":"Deeg","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.09.007_bib46","first-page":"939","article-title":"CD8 depleted donor lymphocytes for CML relapsing post BMT","volume":"23","author":"Champlin","year":"1995","journal-title":"International Society for Experimental Hematology"},{"key":"10.1016\/j.beha.2007.09.007_bib47","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2141.2005.05513.x","article-title":"Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma","volume":"129","author":"Kroger","year":"2005","journal-title":"British Journal of Haematology"},{"issue":"Part 1","key":"10.1016\/j.beha.2007.09.007_bib48","first-page":"1021a","article-title":"A phase 1 dose escalation study of a fully human antagonist anti-CD40 antibody, HCD122 (formerly CHIR-12.12) in patients with relapsed and refractory multiple myeloma","volume":"108","author":"Bensinger","year":"2006","journal-title":"Blood"},{"issue":"Part 1","key":"10.1016\/j.beha.2007.09.007_bib49","first-page":"986a","article-title":"CS1: a potential new therapeutic target for the treatment of multiple myeloma","volume":"108","author":"Hsi","year":"2006","journal-title":"Blood"},{"issue":"Part 1","key":"10.1016\/j.beha.2007.09.007_bib50","first-page":"723a","article-title":"A phase I humanized anti-CD40 monoclonal antibody (SGN-40) in patients with multiple myeloma","volume":"106","author":"Hussein","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.09.007_bib51","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.bmt.1705161","article-title":"Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma","volume":"36","author":"Gerull","year":"2005","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.beha.2007.09.007_bib52","first-page":"77","article-title":"Non-myeloablative allogeneic peripheral stem cell transplantation for multiple myeloma","volume":"10","author":"Ma","year":"2004","journal-title":"Hong Kong Medical Journal"},{"key":"10.1016\/j.beha.2007.09.007_bib53","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bbmt.2006.02.003","volume":"12","author":"Couriel","year":"2006","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"Part 1","key":"10.1016\/j.beha.2007.09.007_bib54","first-page":"901a","article-title":"Unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with high risk multiple myeloma","volume":"108","author":"Sorasio","year":"2006","journal-title":"Blood"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692607000734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692607000734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T12:39:46Z","timestamp":1588595986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692607000734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S1521692607000734"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2007.09.007","relation":{},"ISSN":["1521-6926"],"issn-type":[{"type":"print","value":"1521-6926"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}